Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease.

Plevris, Nikolas; Jenkinson, Philip W; Chuah, Cher S; Lyons, Mathew; Merchant, Lynne M; Pattenden, Rebecca J; Arnott, Ian D; Jones, Gareth R; Lees, Charlie W

Plevris, Nikolas; Jenkinson, Philip W; Chuah, Cher S; Lyons, Mathew; Merchant, Lynne M; Pattenden, Rebecca J; Arnott, Ian D; Jones, Gareth R; Lees, Charlie W.

Afiliación

Plevris N; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Jenkinson PW; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Chuah CS; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Lyons M; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Merchant LM; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Pattenden RJ; Department of Biochemistry, Western General Hospital, Edinburgh, UK.
Arnott ID; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Jones GR; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Lees CW; The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.

Frontline Gastroenterol ; 11(2): 117-123, 2020 Mar.

Article en En | MEDLINE | ID: mdl-32133110

Palabras clave

crohn's disease; therapeutic drug monitoring; ulcerative colitis; vedolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Frontline Gastroenterol Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google